Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide Versus Rituximab and Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma

NCT07562022 is registered in ClinicalTrials.gov with Sinocelltech Ltd. as lead sponsor.

NCT NCT07562022
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07562022 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide Versus Rituximab and Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
Lead sponsor
Sinocelltech Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
June 9, 2026
Completion date
June 30, 2029
Enrollment
93 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma (fl)